Combined Therapy for Inflammatory Breast Cancer
William L. Donegan, MD;
Brian Padrta, MD
Arch Surg. 1990;125(5):578-582.
Abstract
| |
• The prognosis for patients with inflammatory breast cancer has improved in recent years. This review was undertaken to evaluate current management in three Milwaukee (Wis) hospitals and to identify determinants of prognosis. We identified 25 patients with inflammatory breast carcinoma diagnosed between 1967 and 1987. Most of the patients were treated with combination chemotherapy and radiation therapy, and 10 had mastectomies. The 5-year survival of patients without initial distant metastases was 24%. The 5-year survival of patients who received chemotherapy before local treatment was 40%. Patients who had clinically involved axillary nodes or a palpable mass in the breast had poorer survival than those who did not; the presence of dermal lymphatic invasion had no significant effect on survival. Initial chemotherapy has become an important part of the care of patients with inflammatory breast cancer. It remains uncertain whether mastectomy improves on irradiation in achieving local control or improves survival.
(Arch Surg. 1990;125:578-582)
Author Affiliations
From the Departments of Surgery, Medical College of Wisconsin and Sinai Samaritan Medical Center, Milwaukee.
Footnotes
Accepted for publication October 19, 1989.
Reprints not available.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Inflammatory Breast Carcinoma and Noninflammatory Locally Advanced Breast Carcinoma: Distinct Clinicopathologic Entities?
Anderson et al.
JCO 2003;21:2254-2259.
ABSTRACT
| FULL TEXT
Inflammatory Breast Cancer
Moore et al.
Arch Surg 1991;126:304-306.
ABSTRACT
|
